Nephros, Inc.
NEPH
$1.62
-$0.04-2.41%
| Weiss Ratings | NEPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | NEPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | NEPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.02 | |||
| Price History | NEPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 10.96% | |||
| 30-Day Total Return | -2.99% | |||
| 60-Day Total Return | 4.52% | |||
| 90-Day Total Return | 11.72% | |||
| Year to Date Total Return | 10.96% | |||
| 1-Year Total Return | -25.00% | |||
| 2-Year Total Return | 57.28% | |||
| 3-Year Total Return | -59.19% | |||
| 5-Year Total Return | -72.96% | |||
| 52-Week High % Change | -36.47% | |||
| 52-Week Low % Change | 18.74% | |||
| Price | NEPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $2.55 | |||
| 52-Week Low Price | $1.36 | |||
| 52-Week Low Price (Date) | Oct 24, 2024 | |||
| 52-Week High Price (Date) | May 17, 2024 | |||
| Valuation | NEPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 17.08M | |||
| Enterprise Value | 14.73M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.09 | |||
| Earnings Per Share Growth | -55.91% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 1.27 | |||
| Price/Book (Q) | 2.09 | |||
| Enterprise Value/Revenue (TTM) | 1.09 | |||
| Price | $1.62 | |||
| Enterprise Value/EBITDA (TTM) | -18.26 | |||
| Enterprise Value/EBIT | -15.35 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | NEPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 10.58M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | NEPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 201 343 5202 | |||
| Address | 380 Lackawanna Place South Orange, NJ 07079 | |||
| Website | www.nephros.com | |||
| Country | United States | |||
| Year Founded | 1997 | |||
| Profitability | NEPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -7.08% | |||
| Profit Margin | -6.85% | |||
| Management Effectiveness | NEPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -5.63% | |||
| Return on Equity | -- | |||
| Income Statement | NEPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 13.55M | |||
| Total Revenue (TTM) | 13.55M | |||
| Revenue Per Share | $1.28 | |||
| Gross Profit (TTM) | 8.27M | |||
| EBITDA (TTM) | -807.00K | |||
| EBIT (TTM) | -960.00K | |||
| Net Income (TTM) | -929.00K | |||
| Net Income Avl. to Common (TTM) | -929.00K | |||
| Total Revenue Growth (Q YOY) | -5.99% | |||
| Earnings Growth (Q YOY) | 200.55% | |||
| EPS Diluted (TTM) | -0.09 | |||
| EPS Diluted Growth (Q YOY) | 187.00% | |||
| Balance Sheet | NEPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 2.46M | |||
| Cash Per Share (Q) | $0.23 | |||
| Total Current Assets (Q) | 7.36M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 8.17M | |||
| Current Ratio (Q) | 6.953 | |||
| Book Value Per Share (Q) | $0.78 | |||
| Total Assets (Q) | 10.39M | |||
| Total Current Liabilities (Q) | 1.06M | |||
| Total Debt (Q) | 1.49M | |||
| Total Liabilities (Q) | 2.21M | |||
| Total Common Equity (Q) | 8.17M | |||
| Cash Flow | NEPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -125.00K | |||
| Cash from Financing (TTM) | -7.00K | |||
| Net Change in Cash (TTM) | -2.17M | |||
| Levered Free Cash Flow (TTM) | -1.63M | |||
| Cash from Operations (TTM) | -2.03M | |||
